Table 1.
Patient characteristics
| Characteristics | Ctl (non-obese) | Obese |
|---|---|---|
| Patients, n | 6 | 9 |
| Male gender, n (%) | 4 (80) | 6 (67) |
| Age (years), mean±SD | 73 ± 6 | 71 ± 5 |
| BMI (kg/m2), mean±SD | 25 ± 1 | 34 ± 2* |
| CAD, n (%) | 0 (0) | 4 (44) |
| AVD/MVD, n (%) | 2 (33) | 3 (33) |
| CAD+AVD/MVD, n (%) | 4 (67) | 2 (22) |
| Hypertension, n (%) | 5 (83) | 5 (55) |
| Hyperlipidemia, n (%) | 3 (50) | 8 (89)* |
| LA diameter (mm), mean±SD | 47 ± 1 | 45 ± 8 |
| LVEF (%), mean±SDa | 60 ± 6a | 56 ± 9a |
| Oral antidiabetic drugs, n (%)b | 0 (0) | 8 (89)* |
| Insulin, n (%) | 0 (0) | 8 (89)* |
| ACEI/ARB, n (%) | 5 (83) | 6 (67) |
| Beta blockers, n (%) | 1 (17) | 6 (67) |
| Calcium channel blockers, n (%) | 0 (0) | 1 (11) |
| Digitalis glycosides, n (%) | 0 (0) | 0 (0) |
| Diuretics, n (%) | 1 (17) | 5 (55) |
| Lipid-lowering drugs, n (%) | 3 (50) | 7 (78) |
| Oral anticoagulants, n (%) | 0 (0) | 0 (0) |
| Nitrates, n (%) | 0 (0) | 0 (0) |
| Platelet inhibitors, n (%) | 3 (50) | 8 (89) |
| CRP (mg/dL), mean±SD | 0.75 ± 0.6 | 0.67 ± 0.52 |
| Leucocytes (/nL), mean±SD | 7.8 ± 1.4 | 8.7 ± 2.6 |
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; AVD, aortic valve disease; BMI, body mass index; CAD, coronary artery disease; CRP, C-reactive protein; LA, left atrial; LV, left ventricular; MI, myocardial infarction; MVD, mitral valve disease; SD, standard deviation.
*
P < 0.05 determined by Wilcoxon rank sum test for continuous variables, and Fisher’s exact test for categorical values.
a
Data missing from n = 2 Control and n = 4 Obese patients.
b
Metformin (n = 3), Sitagliptin (n = 3), Glibenclamide (n = 1), Dapagliflozin (n = 1).